The United States Agency for International Development (USAID), in collaboration with Swiss Pharma (Swipha), has achieved a groundbreaking milestone in the pharmaceutical industry, marking a significant advancement in healthcare across Nigeria and West Africa.
Through this partnership, Swipha has become the first pharmaceutical company in the region to receive World Health Organization (WHO) prequalification for two essential medicines, a step that is set to enhance access to life-saving treatments.
Historically, Nigeria has grappled with challenges in accessing affordable, high-quality medicines, largely due to the inability of local pharmaceutical companies to meet stringent international standards. These challenges have particularly affected vulnerable groups such as children and pregnant women. However, with USAID’s technical support, Swipha has not only secured WHO prequalification but also established itself as a pioneer in complying with WHO Good Manufacturing Practice standards in Nigeria and West Africa.
The newly certified pediatric Zinc Sulphate, crucial for mitigating severe diarrhea among children under five, and the WHO-certified Sulfadoxine-pyrimethamine tablets, essential for preventing malaria during pregnancy, are set to make a significant impact on public health. Swipha’s WHO prequalification now enables the company to supply these critical medicines to international organizations and governments, bolstering child and maternal health throughout Nigeria, the West African sub-region, and beyond.
During a visit to Swipha’s Lagos facility, USAID Acting Mission Director Alexis Taylor-Granados highlighted the importance of this achievement, stating, “This milestone showcases the power of collaboration in advancing healthcare in Nigeria. We are proud to have supported Swipha in reaching this level of excellence and are committed to ensuring that more quality medicines reach those who need them most. Together, we are building a healthier future for Nigeria.”
